Systematic (IUPAC) name
Clinical data
Pregnancy cat.  ?
Legal status Uncontrolled
Routes Oral
Pharmacokinetic data
Metabolism Liver (CYP2D6)[1]
CAS number 61337-87-9
ATC code None
PubChem CID 3085218
ChemSpider 2342166 YesY
UNII 4685R51V7M YesY
KEGG D04055 YesY
Chemical data
Formula C21H23N3O4 
Mol. mass 381.43 g/mol
SMILES eMolecules & PubChem
Physical data
Melt. point 114–116 °C (237–241 °F)
Solubility in water Soluble in methanol and chloroform mg/mL (20 °C)
 YesY(what is this?)  (verify)

Esmirtazapine (ORG-50,081) is a drug which is under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause.[2][3][4][5] As of 2009 it is in phase III clinical trials.[2] Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors.[2][6] As of March 2010, Merck terminated internal clinical development program for esmirtazapine, for hot flashes and insomnia, for strategic reasons.[7]

See also